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DNA gyrase is the only enzyme known to negatively
supercoil DNA. The enzyme is a heterotetramer of A2B2
subunit composition. Alignment of the primary se-
quence of gyrase B (GyrB) from various species shows
that they can be grouped into two classes. The GyrB of
Gram-negative eubacteria has a stretch of about 165
amino acids in the C-terminal half, which is lacking in
other GyrB subunits and type II topoisomerases. In
Escherichia coli, no function has so far been attributed
to this stretch. In this study, we have tried to assess the
function of this region both in vivo and in vitro. A delet-
ant (GyrBD160) lacking this region is non-functional in
vivo. The holoenzyme reconstituted from gyrase A
(GyrA) and GyrBD160 shows reduced but detectable su-
percoiling and quinolone-induced cleavage activity in
vitro. GyrBD160 retains its ability to bind to GyrA and
novobiocin. However, when reconstituted with GyrA,
the deletant shows greatly impaired DNA binding. The
intrinsic ATPase activity of the GyrBD160 is comparable
to that of wild type GyrB, but this activity is not stimu-
lated by DNA. These studies indicate that the additional
stretch present in GyrB is essential for the DNA binding
ability of E. coli gyrase.
Topoisomerases are a ubiquitous class of enzymes that cat-
alyze the interconversion between different topological isomers
of DNA (1, 2). Among these enzymes, DNA gyrase is the only
enzyme that has the ability to negatively supercoil DNA (3, 4).
In addition to supercoiling, gyrase can relax both positively and
negatively supercoiled DNA and catalyze catenation/decatena-
tion as well as knotting/unknotting reactions (4). Gyrase per-
forms these topological transformations by creating transient
double-stranded breaks in DNA and resealing the break after
passing another DNA duplex through it (2). Hence, mechanis-
tically the enzyme is a type II topoisomerase.
DNA gyrase is an essential enzyme and belongs exclusively
to the prokaryotic kingdom. Although gyrases from various
species show resemblance to eukaryotic type II topoisomerases,
they have diverged significantly during evolution and have
enzymatic properties distinct from other members of this class.
Therefore, the enzyme is an effective target for many antibac-
terial agents (5, 6), some of which are used clinically as drugs.
Two major classes of drugs that inhibit gyrase are quinolones
and coumarins.
DNA gyrase is a heterotetramer consisting of two GyrA1 and
two GyrB polypeptides (4). The gyrA and gyrB genes have been
cloned and sequenced from a variety of bacterial species (7), but
most of the biochemical as well as the structural studies have
centered on the enzyme from Escherichia coli. The GyrA and
GyrB proteins have been shown to be organized as functional
domains (4). The GyrA protein consists of an N-terminal do-
main (59–64 kDa) that harbors the DNA cleavage-reunion
activity (8, 9) and a C-terminal 33-kDa region involved in
wrapping the DNA (10). The GyrB protein consists of an N-
terminal domain (43 kDa) that hydrolyzes ATP and binds to
coumarin drugs (11, 12). The intrinsic ATPase activity of GyrB
is stimulated by the presence of GyrA and DNA (13, 14). The
C-terminal 47-kDa fragment of GyrB can complement the in-
tact GyrA to form a complex that retains the ability to relax
supercoiled DNA in the absence of ATP (11, 15). Therefore this
part of the protein has been postulated to bind to GyrA and
DNA. The exact region(s) involved in these functions have yet
to be characterized.
Sequence alignment of GyrB proteins from different organ-
isms (Fig. 1) reveals the absence of a stretch of about 165 amino
acids from Gram-positive bacteria and mycoplasma (7, 16, 17).
This stretch is also missing from eukaryotic topoisomerase II
enzymes as well as from the homologues of GyrB in topoisomer-
ase IV from different species. The structural information about
type II topoisomerases is derived from the structure of an
internal fragment of yeast topoisomerase II (18), the N-termi-
nal ATPase domain of E. coli GyrB (19), and the N-terminal
two-thirds of the E. coli GyrA (20). However, none of the struc-
tures include the 165-amino acid region. Furthermore, this
region has not been implicated in any specific function.
In the present study, we have tried to assess whether the
additional amino acid stretch present in GyrB of E. coli is
essential for the function of the enzyme. We have created a
truncated GyrB by deleting 160 amino acids within the extra
165-amino acid region in the full-length protein. The deletant
GyrB (GyrBD160) has been purified, and its enzyme activities
have been compared with GyrB. We have determined the max-
imal dispensable region in this particular stretch of amino
acids without changing the ability of the protein to rescue the
temperature-sensitive strain of GyrB. We find that the region
is essential for the DNA binding ability of the active gyrase
tetramer. Deletion of this stretch impairs the activity of the
protein both in vivo and in vitro.
EXPERIMENTAL PROCEDURES
Bacterial Strains and Plasmids—E. coli DH10B was used for all
cloning experiments. The strain N4177 (gyrBts cour) was a kind gift* This work was supported by a grant from Department of Biotech-
nology, Government of India. The costs of publication of this article
were defrayed in part by the payment of page charges. This article must
therefore be hereby marked “advertisement” in accordance with 18
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¶ To whom correspondence should be addressed. Tel.: 91 80 3092598
or 91 80 3600668; Fax: 91 80 3602697; E-mail: vraj@mcbl.iisc.ernet.in.
1 The abbreviations used are: GyrA, DNA gyrase A protein; GyrB,
DNA gyrase B protein; GyrBD160, GyrB protein lacking 160 amino
acids; PCR, polymerase chain reaction; EMSA, electrophoretic mobility
shift assay.
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from M. Gellert (21). Overexpression plasmids pPH3 and pAG111 (22)
were used for GyrA and GyrB purification, respectively. The plasmid
pJW312-SalI used in the purification of E. coli topoisomerase I was
obtained from J. C. Wang (23).
DNA Manipulations—GyrBD160 was generated by PCR amplifying
parts of the gene upstream and downstream of the 160-amino acid
stretch using the primers P1 and P2 and primers P3 and P4, respec-
tively. The primer sequences are as follows: P1, 59-ACAGCGATGTC-
GAATTCTTATG; P2, 59-TTGCGCCCTCGAGCGCGATAGAGATC; P3,
59-GTAGCCAGCCTCGAGCAGGCGCT; P4, 59-GGCCAGTGCCAAGC-
TTGCATG. The PCR products were digested with appropriate restric-
tion enzymes and cloned (pMCN1 and pMCN2) separately in pBlue-
script KS(1) (Stratagene). The relevant portions were sequenced, and
then the fragments were brought together in pBluescript KS(1)
(pMCN3) resulting in the generation of an XhoI site at the junction. The
SalI-HindIII region of GyrB present in pAG111 was replaced with the
SalI-HindIII fragment from pMCN3, which encompasses the deletion to
generate GyrBD160 (pMCN4, Fig. 2).
Two more deletions mutant of GyrB were created, one lacking the
first 78 amino acids of the 160-amino acid stretch and the other where
the following 84 amino acids were removed (pMCN6 and pMCN5, Fig.
2). pMCN5 and pMCN6 were generated by replacing appropriate (SalI-
XhoI and XhoI-HindIII, respectively) fragments in pMCN4 with frag-
ments from pAG111-XhoI.
For the purpose of generating a range of exonuclease III-mediated
deletions (within the 160-amino acid stretch), an XhoI site was engi-
neered near the center of the region in the full-length GyrB (pAG111-
XhoI) (Fig. 2) using the QuikChangeTM mutagenesis method (Strat-
agene). The mutagenesis was carried out using the following primers:
59-GTCAGCGAACTCGAGGACAAAGAACAG and 59-CTGTTCTTT-
GTCCTCGAGTTCGCTGAC with pAG111 as the template. pAG111-
XhoI linearized with XhoI was used as the substrate for the exonuclease
III reaction (24). Aliquots were taken out at different time intervals
(15–120 s), and the DNA ends were blunted using S1 nuclease and
Klenow fragment of DNA polymerase I. After ligation, the DNA was
transformed into strain N4177 for complementation studies.
Complementation Studies—gyrBts strain N4177 was used for all
complementation studies. After transformation, the cells were recov-
ered at 30 °C and plated at the permissive (30 °C) or restrictive tem-
perature (42 °C). In all the complementation experiments, cells trans-
formed with pAG111 were used as a positive control and pTTQ18 as the
negative control.
Enzymes and Substrate Preparation—GyrA and GyrB were purified
as described previously (25). GyrBD160 was purified using the similar
purification scheme as used for GyrB except that a gradient of 0–1 M
NaCl was used to elute the protein from the Hi-Trap heparin-Sepharose
column. GyrBD160 was also purified using a novobiocin-Sepharose
affinity column as described previously (25). The protein was purified
from N4177 cells harboring pMCN4. Supercoiled pUC18 and pBR322
were prepared by standard DNA purification protocols (24). E. coli
topoisomerase I was purified, and relaxed pUC18 was prepared as
described by Lynn and Wang (23).
Assays—Supercoiling assays were carried out as described by Miz-
zuuchi et al. (26). Ciprofloxacin-induced cleavage was performed in
supercoiling buffer except that ATP was omitted and supercoiled
pBR322 was used as the substrate. Ciprofloxacin was added at a final
concentration of 100 mg/ml. The reaction was carried out at 37 °C for 30
min and the drug-gyrase-DNA complex was trapped by adding 0.2%
FIG. 1. Alignment of primary se-
quences of GyrB homologues from
different organisms. The alignment in-
cludes GyrB from Gram-negative eubac-
teria (EcB, E. coli; PpB, Pseudomonas
putida), Gram-positive eubacteria (BsB,
Bacillus subtilis; MtB, Mycobacterium tu-
berculosis), archaea (AfB, Archaeoglobus
fulgidus; HaB, Haloferax alicantei), and
Mycoplasma pneumoniae (MpB); ParE
from E. coli (EcE), GrlB from Staphylococ-
cus aureus (SaE); and partial sequence of
topoisomerase II from Saccharomyces cer-
evisiae (Sct) and Homo sapiens (Hst). The
length of each sequence is shown on the
right. Alignment was performed using
MACAW software (35). Blocks denote re-
gions of extended homology. Regions with
greater than 67% similarity are in black
and those with 37–67% similarity are in
gray.
FIG. 2. Derivatives of GyrB used in this study. a, schematic
representation of various GyrB derivatives. The relevant restriction
sites have been denoted on the gyrB gene (thick line). Derivatives of the
GyrB protein are shown with the junctions generated as a result of
various deletions. The XhoI site engineered in pAG111-XhoI causes a
single amino acid change (N637E). The regions between Ala-559 and
Gln-720, Glu-635 and Gln-720, and Ala-559 and Asp-638 are deleted in
pMCN4 (GyrBD160), pMCN5, and pMCN6, respectively. In all three
deletants, two amino acids (lysine and glutamate) are added at the
junction. b, induction profile of N4177 cells transformed with different
constructs. The cells were grown at 30 °C until A600 5 0.5 and induced
with 50 mM isopropylthiogalactoside for 4 h. Purified GyrA, GyrB, and
GyrBD160 are also shown.
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SDS. After 5 min, proteinase K was added at a final concentration of 0.8
mg/ml and incubated for 30 min. The reaction mixtures were resolved
on 0.8% agarose gel in 40 mM Tris acetate buffer containing 1 mM
EDTA. The gel was run at 1.5 V/cm for 6 h.
ATPase Assays—ATPase assays were performed as described previ-
ously (27). The reactions (30 ml each) were carried out in supercoiling
buffer containing 2 mM ATP and 0.04 mCi of [a-32P]ATP (.5000 Ci/
mmol, NEN Life Science Products). The reaction was performed at
37 °C for 30 min and terminated by adding chloroform. 5 ml of the
aqueous layer was resolved on a polyethyleneimine-cellulose thin layer
chromatography plate (Merck), which was developed with 1.2 mM LiCl
and 0.1 mM EDTA. The spots corresponding to ADP and ATP were
quantitated using a PhosphorImager (Fuji Film FLA2000). Sonicated
salmon sperm DNA (150 mg/ml) was used wherever indicated.
Electrophoretic Mobility Shift Assay—EMSA was performed using a
PCR-amplified 240-base pair fragment encompassing the preferred gy-
rase cleavage site in pBR322 (28). The primers used for the amplifica-
tion were end-labeled with [g-32P]ATP by T4 polynucleotide kinase
prior to PCR. The labeled DNA fragment was gel-eluted and purified
through Sephadex G-50 (Amersham Pharmacia Biotech). Gyrase was
reconstituted in supercoiling buffer (tRNA and ATP were omitted) and
incubated with labeled DNA at 4 °C for 1 h. The free DNA and the
gyrase-DNA complex were separated using 5% polyacrylamide gel (29:1
acrylamide/N,N9-methylenebisacrylamide) in 90 mM Tris borate, 5 mM
MgCl2. The gel was run at 4 °C at 5 V/cm for 8 h, autoradiographed, and
quantitated using a PhosphorImager.
Novobiocin-Sepharose Column—Novobiocin was coupled to Sepha-
rose as described before (25). GyrB was loaded, and the column was
washed with TGED (TGED, 50 mM Tris-HCl (pH 7.5), 5% (v/v) glycerol,
1 mM EDTA, and 1 mM dithiothreitol). GyrA was loaded, and the column
was successively washed with TGED containing 0 M KCl, 1 M KCl, 2 M
urea, and 6 M urea. Samples from each wash were analyzed by SDS-
polyacrylamide gel electrophoresis to determine the elution of GyrB and
GyrA. GyrBD160 was also analyzed under similar experimental
conditions.
Surface Plasmon Resonance—Surface plasmon resonance experi-
ments were performed on a BIAcore 2000 system (BIAcore). GyrA was
immobilized on the CM5 sensor chip via amine coupling in acetate
buffer (pH 4.5). The surface was blocked with ethanolamine hydrochlo-
ride. The interaction was assessed in 10 mM HEPES-NaOH (pH 7)
containing 150 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol. Proteins
used for the experiment were dialyzed against running buffer prior to
the experiment. Different concentrations of GyrB and GyrBD160 were
passed over the immobilized GyrA, and the subsequent changes in
resonance units were recorded. Buffer containing 1 M KCl was used to
dissociate bound GyrB or GyrBD160 from GyrA after each run.
RESULTS
Alignment of the primary sequences of type II topoisomer-
ases shows the presence of an extra 165-amino acid stretch in
GyrBs of Gram-negative organisms (Fig. 1). ParE, the GyrB
homologue in topoisomerase IV from E. coli, however, lacks this
region. GyrB from archaea as well as topoisomerase II from
eukaryotes also do not have this region. To assess the function
of this stretch, we created a deletant of E. coli GyrB that lacked
160 amino acids from the C-terminal domain of the protein
(pMCN4, Fig. 2a). In addition we also generated two “partial”
deletants that lack either the N-terminal (pMCN6) or the C-
terminal (pMCN5) halves of the 160 amino acids.
GyrB Lacking 160 Amino Acids Fails to Rescue the gyrBts
Strain—The E. coli strain N4177 carries a temperature-sensi-
FIG. 3. In vivo complementation
analysis of gyrBts strain by various
deletants. a, N4177 (gyrBts) cells were
transformed with pTTQ18 (region 1),
pAG111 (region 2), pMCN4 (region 3),
pMCN5 (region 4), pMCN6 (region 5), and
pAG111-XhoI (region 6). Cells trans-
formed with representative non-comple-
menting (region 7) or complementing
(region 8) clones generated in the exonu-
clease III experiment are also shown. b,
schematic representation of exonuclease
III-mediated deletions. All clones overex-
press the protein of the expected size.
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tive allele of gyrB. pAG111 (plasmid expressing full-length
GyrB) is able to rescue the cells at the restrictive temperature.
On the other hand, cells expressing any of the three deletants
were unable to grow at restrictive temperature (Fig. 3a) even
when the expression was induced with isopropylthiogalacto-
side. Comparable amounts of the deletant proteins were pres-
ent in cells with respect to the expression of full-length GyrB
(Fig. 2b), and around 90% of the proteins were soluble after
induction (data not shown). Furthermore, immunoblots using
monoclonal antibody against GyrB showed that the steady
state level of the deletants was very similar to GyrB in the
uninduced state. Thus the deletants were being expressed and
had similar stability in vivo as the full-length GyrB. These
results imply that the inability to rescue the gyrBts strain was
due to the impaired activity of the deletants in vivo and not
because of their lack of expression, solubility, or rapid
degradation.
Exonuclease III-mediated Deletions—A range of deletions
within the 165-amino acid region was generated using exonu-
clease III. Restriction analysis and the protein expression pro-
file indicated that a large range of in-frame deletions was
obtained. Under our experimental conditions, no clones were
obtained that had the entire 165-amino acid region removed
and yet was able to rescue gyrBts strain (Fig. 3b). Among the
clones that rescued the gyrBts strain, those harboring the larg-
est deletions were sequenced to determine the precise junc-
tions. The largest region that could be removed without ham-
pering the protein function in vivo was comprised of the central
50 amino acids (621–670, Fig. 3a, segment 8).
The Deletant Shows Reduced Supercoiling and Cleavage Ac-
tivity in Vitro—The GyrBD160 protein was purified from
N4177 cells harboring pMCN4 (see “Experimental Procedures,”
Fig. 2b). The ability of the purified GyrBD160 to support su-
percoiling in the presence of GyrA and ATP was assessed at 30
and 42 °C. The protein showed extremely reduced (,2% of the
wild type) supercoiling activity at both temperatures. Fig. 4a
depicts one such supercoiling assay performed at 42 °C. In
addition, the activity was inhibited in the presence of novobio-
cin. It is noteworthy that the strain N4177 harbors a temper-
ature-sensitive allele of gyrB, which shows no detectable activ-
ity at 42 °C (21, 29) and is resistant to novobiocin at 30 °C (21).
Thus, the above results clearly demonstrate that the supercoil-
ing activity is specific to the holoenzyme composed of GyrA and
GyrBD160. Quinolones (e.g. ciprofloxacin) are known to trap
the covalent enzyme-DNA intermediate in the topoisomeriza-
tion reaction and have been used to assess the cleavage activity
of DNA gyrase holoenzyme (30). The deletant showed 80-fold
reduction in ciprofloxacin-induced cleavage, paralleling the re-
sults obtained with the supercoiling assay (Fig. 4b).
Deletant Binds to Novobiocin and GyrA—To ensure that the
reduced specific activity was not due to improper folding of the
deletant, the other properties exhibited by GyrB were exam-
ined. The N-terminal region of GyrB is known to bind to cou-
marins (e.g. novobiocin). GyrB interacts very tightly to novo-
biocin, and this has proved useful in the purification of the
protein (13). Novobiocin coupled to epoxy-activated Sepharose
serves as an affinity handle to assess the binding of gyrB to the
drug. Moreover, GyrB bound to novobiocin on the column re-
tains its ability to interact with GyrA. The deletant was re-
tained, when passed through such a novobiocin-affinity col-
umn, exhibiting the property characteristic of wild type GyrB.
In addition, GyrA interacted with the deletant bound to the
column (not shown) indicating that the overall tertiary struc-
ture of the deletant was unaltered. The GyrBD160 and GyrA
interaction was quantitatively evaluated using the BIAcore
system. For this purpose, GyrA was immobilized on a CM-5
sensor chip. Various concentrations of analyte (GyrB or
GyrBD160) were passed over the sensor surface, and the sub-
sequent changes in resonance units were recorded. The kinetic
parameters obtained show that the deletant bound to GyrA
with an affinity comparable to the full-length GyrB (Table I).
Furthermore, when GyrB was immobilized and GyrA was
passed over the surface, similar results (KD 5 2.1 3 10
27 M)
were obtained, substantiating the authenticity of the
interaction.
The Holoenzyme Comprising GyrA and GyrBD160 Is Im-
paired in DNA Binding—EMSAs were carried out to assess the
FIG. 4. Holoenzyme comprising GyrA and GyrBD160 shows
reduced supercoiling and cleavage activity. a, supercoiling activ-
ity, 30 pmol of GyrA was used in all reactions. 0.3 pmol of GyrB was
added in lanes 3 and 4. GyrBD160 was added as follows: 1.5 (lanes 5 and
6), 5 (lanes 7 and 8), and 15 pmol (lanes 9 and 10). Novobiocin (60 pmol)
was added wherever indicated. The reactions were performed at 42 °C
for 30 min. Lanes 1 and 2 have supercoiled (S) and relaxed (R) pUC18,
respectively. b, ciprofloxacin-induced cleavage reaction; GyrA was
added as follows: 6 (lanes 3 and 4), 30 (lanes 5–7), 10 (lanes 8–10), and
3 pmol (lanes 11-13). 3 pmol of GyrB was added in lanes 3 and 4.
GyrBD160 was added as follows: 15 (lanes 6 and 7), 5 (lanes 9 and 10),
and 1.5 pmol (lanes 12 and 13). Ciprofloxacin (100 mg/ml) was added
wherever indicated. The covalent gyrase-DNA complex was trapped
with SDS (0.2%) and digested with proteinase K (0.8 mg/ml) for 30 min
at 37 °C. Supercoiled pBR322 (S) was used as the substrate for the
reaction, and the formation of linear pBR322 (L) was monitored. Lane
1 shows 1-kilobase pair ladder (Life Technologies, Inc.).
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binding of gyrase to DNA. The holoenzyme comprising GyrA
and GyrB bound to DNA in a concentration-dependent manner
(Fig. 5a). However, the enzyme reconstituted from GyrA and
GyrBD160 showed no detectable stable complex even when
much higher amounts of protein were used (Fig. 5b). Thus, it
appears that the removal of the 165-amino acid region from
GyrB affects the DNA binding ability of the holoenzyme. Since
the deletant binds to GyrA, we wanted to assess its effect on the
formation of A2B2 holoenzyme in an EMSA reaction. When
GyrA was mixed with fixed and limiting amount of GyrB and
varying amounts of GyrBD160, there was a concentration-de-
pendent increase in the amount of complex formed (Fig. 6a).
However, with limiting GyrA, there was reduction in the
amount of gyrase-DNA complex formed with the increase in
GyrBD160 (Fig. 6b). These results are in accordance with a
scenario where GyrBD160 is defective in DNA binding but not
in its interaction with GyrA (see “Discussion”).
The ATPase Activity of the Deletant Is Not Stimulated by the
Presence of GyrA and DNA—The ATPase activity of GyrB and
GyrBD160 was assessed in the absence and presence of DNA.
The intrinsic ATPase activity of the enzymes in the absence of
DNA was similar (Fig. 7, Km, GyrB, 1.4 mM and GyrBD160, 1.6
mM). In the presence of DNA, there was stimulation in ATP
hydrolysis by GyrB, whereas the deletant showed no apprecia-
ble change in activity. Taken together, these findings agree
well with the failure of the A2DB2 holoenzyme to bind DNA.
DISCUSSION
The present study is an attempt to understand the function
of the extra 165 amino acids present in GyrB of E. coli. We find
that the region plays an essential role in the functioning of E.
coli DNA gyrase. This region is present only in Gram-negative
organisms. In contrast, other homologues of GyrB in all three
kingdoms (eukarya, archaea, and Gram-positive eubacteria)
lack this region. It is also absent from topoisomerase IV belong-
ing to both Gram-positive and Gram-negative eubacteria.
Our analysis shows that truncated E. coli GyrBs, lacking the
stretch (GyrBD160), or lacking half of the region are unable to
rescue a gyrBts strain (Fig. 3). Thus the deletants appear to be
non-functional in vivo despite being expressed at high levels
with .90% in the soluble form. In addition, exonuclease III-
mediated deletion analysis revealed that deletions greater than
50 amino acids (near the center of the stretch) rendered the
protein inactive in vivo. This further confirms that the stretch
is essential for the functioning of GyrB in E. coli.
We purified GyrBD160 to analyze its biochemical properties
in vitro. The purified GyrBD160 retains novobiocin binding (not
shown), GyrA binding (Table I), and has similar intrinsic
ATPase activity to full-length GyrB (Fig. 7a). Thus, it appears
that the removal of 160 amino acids within the 165-amino acid
stretch does not grossly disturb the overall conformation of the
protein. In contrast, GyrBD160 (in presence of GyrA) is se-
verely compromised in both supercoiling activity and drug-
induced cleavage activity (Fig. 4). Therefore, it appears that the
deletant is dysfunctional in cleavage or a step prior to it. In the
supercoiling reaction cycle of DNA gyrase, prior to cleaving
DNA, GyrB has to bind to GyrA and form an active heterotet-
ramer. Thus, the reduced cleavage by the deletant may be due
to its inability to bind GyrA, inefficient heterotetramer forma-
tion, reduced DNA binding ability, or poor cleavage activity per
se. We find that the deletion does not affect the interaction of
FIG. 5. Holoenzyme comprised of
GyrBD160 fails to bind to DNA.
EMSAs were performed with holoenzyme
composed of GyrA-GyrB (a) and GyrA-
GyrBD160 (b). 300 fmol of DNA and 200
nM GyrA were used in all reactions. Vary-
ing amounts of GyrB (a) and GyrBD160
(b) were added as indicated. The reactions
were incubated for 1 h at 4 °C and re-
solved in a 5% polyacrylamide gel.
TABLE I
Kinetic parameters of the interaction of GyrA with GyrB and GyrBD160
Protein kon koff KD
M
21 s21 s21 M
GyrB 1.73 3 103 6 0.21 3 103 1.17 3 1023 6 0.12 3 1023 6.83 3 1027 6 1.63 3 1027
GyrD160 0.93 3 103 6 0.19 3 103 0.32 3 1023 6 0.07 3 1023 3.47 3 1027 6 0.21 3 1027
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GyrB with GyrA (Table I); however, the deletant shows a dras-
tic reduction in DNA binding. There is no detectable stable
gyrase-DNA complex seen in EMSAs with the gyrase (A2DB2)
holoenzyme (Fig. 5b). Under similar conditions, the wild type
(A2B2) holoenzyme is able to bind DNA and form a stable
complex (Fig. 5a).
Previous work has suggested that GyrB readily forms het-
erodimers when two populations are mixed (31, 32). Therefore,
it is possible to calculate the proportions of wild type ho-
modimers, mutant homodimer, and heterodimer in a mixed
population. This provides an explanation for the data shown in
Fig. 6. In Fig. 6a, where the concentration of GyrA is high,
increasing amounts of DB lead to an increase in the percentage
of DNA-protein complex. If we assume that A2BDB can bind
DNA, then the increase in the amount of this complex will lead
to an increase in the total amount of DNA bound. In Fig. 6b,
where the concentration of GyrA is limiting, there will be a
competition between the B dimers for GyrA. With increasing
amounts of DB, A2DB2 will predominate. As this species is
known to be incapable of binding to DNA (Fig. 5), the amount
of DNA bound will decrease, as observed. Therefore, these data
support the idea that GyrB exists as a monomer-dimer equi-
librium and suggest that the heterodimer (A2BDB) is capable of
binding to DNA. Taken together, these results indicate that the
deletant is able to bind GyrA but is defective in DNA binding.
It has been shown earlier that the ATPase activity of GyrB is
stimulated in the presence of GyrA and DNA (13, 14). The
intrinsic ATPase activity of the deletant is similar to the wild
type (Fig. 7a). However, this activity is not stimulated in the
presence of GyrA and DNA, supporting the above conclusion.
Topoisomerization reaction, especially supercoiling, involves
a series of complicated steps. In the case of gyrase, strand
transfer requires a duplex to pass through the entire dimer
interface of the protein. During this passage, one would expect
a series of transient DNA-protein interactions. Thus, it is not
surprising that more than one region in DNA gyrase partici-
pates in DNA binding. Full-length GyrA, as well as the C-
terminal domain of GyrA alone, can bind to DNA in the absence
of GyrB, albeit with low affinity (10). The C-terminal 33-kDa
region of GyrA is known to wrap DNA in a positive superhelical
sense. In addition, the N-terminal two-thirds of GyrA contains
FIG. 6. The presence of GyrBD160
alters the complex formation by wild
type gyrase. a, EMSA in the presence of
excess GyrA, 300 fmol of DNA, and 200
nM GyrA was used in all reactions. 50 nM
of GyrB was used wherever indicated. b,
EMSA in the presence of limiting GyrA,
30 fmol of DNA, and 30 nM GyrA was used
in all reactions. 150 nM GyrB was used
wherever indicated. Varying amounts of
GyrBD160 were added as mentioned.
FIG. 7. Kinetics of ATP hydrolysis. Reactions were performed with
600 nM GyrB or GyrBD160. 800 nM GyrA and 1 mM ATP was present in
all reactions. The 1DNA reactions contained, in addition, 150 mg/ml
sonicated salmon sperm DNA. The reactions were incubated at 37 °C
for 30 min and terminated with chloroform. The samples were resolved
on a polyethyleneimine cellulose thin layer chromatography plate.
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the active site tyrosine (4) and is implicated in both covalent
and non-covalent interactions with DNA (20). In the case of
GyrB, there is indirect evidence for DNA binding from at least
three different observations. First, the ATPase activity of GyrB
is stimulated by the presence of DNA in the central cavity
within the GyrB dimer (33). Second, GyrB not only enhances
the stability of the protein-DNA complex but its presence is
essential for the manifestation of the cleavage activity by GyrA.
In accordance with this, the B9 region of yeast topoisomerase II
(equivalent to the C-terminal half of GyrB) has been shown to
harbor amino acids crucial for the cleavage-reunion activity of
the enzyme (34). Third, the C-terminal 47 kDa of GyrB in the
presence of GyrA can support ATP-independent relaxation
(15). Therefore, it has been proposed to be involved in binding
both DNA and GyrA. However, no precise region(s) in GyrB has
been allocated these functions. Our findings indicate that the
domain/region within the 165-amino acid stretch may, directly
or indirectly, be involved in DNA binding.
The 165-amino acid region in GyrB is a characteristic of
Gram-negative eubacteria. Our extensive sequence analysis
has failed to reveal any significant homology with other pro-
teins. Although the stretch shows moderate conservation
among different species, we failed to detect any sequence motif,
which would be indicative of its function. The occurrence of
other functional gyrases lacking this stretch seems to imply
that this region may be dispensable. On the contrary, we find
that the 165-amino acid stretch is essential in E. coli GyrB both
in vivo and in vitro. This raises the possibility that among
gyrases there may be two classes of enzymes that show subtle
differences in their interaction with DNA. A detailed compar-
ative analysis of gyrase from Gram-positive and Gram-nega-
tive organisms needs to be done to understand better the func-
tioning of these proteins and their evolutionary history. It
would also be interesting to look for the types of compensatory
mechanisms/mutations operating in gyrases lacking this
stretch.
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